These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37146210)

  • 1. Risk of ventricular arrhythmias following implantable cardioverter-defibrillator generator change in patients with recovered ejection fraction: Implications for shared decision-making.
    Chang DD; Pantlin PG; Benn FA; Ryan Gullatt T; Bernard ML; Elise Hiltbold A; Khatib S; Polin GM; Rogers PA; Velasco-Gonzalez C; Morin DP
    J Cardiovasc Electrophysiol; 2023 Jun; 34(6):1405-1414. PubMed ID: 37146210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Occurrence of Implantable Cardioverter Defibrillator Therapies After Generator Replacement in Patients Who No Longer Meet Primary Prevention Indications.
    Kawata H; Hirai T; Doukas D; Hirai R; Steinbrunner J; Wilson J; Noda T; Hsu J; Krummen D; Feld G; Wilber D; Santucci P; Birgersdotter-Green U
    J Cardiovasc Electrophysiol; 2016 Jun; 27(6):724-9. PubMed ID: 26915696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normalization of Left Ventricular Ejection Fraction and Incidence of Appropriate Antitachycardia Therapy in Patients With Implantable Cardioverter Defibrillator for Primary Prevention of Sudden Death.
    House CM; Nguyen D; Thomas AJ; Nelson WB; Zhu DW
    J Card Fail; 2016 Feb; 22(2):125-32. PubMed ID: 26522819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ventricular tachyarrhythmia recurrence in primary versus secondary implantable cardioverter-defibrillator patients and role of electrophysiology study.
    Zaman S; Sivagangabalan G; Chik W; Stafford W; Hayes J; Denman R; Young G; Sanders P; Kovoor P
    J Interv Card Electrophysiol; 2014 Dec; 41(3):195-202. PubMed ID: 25267274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone.
    Gali WL; Sarabanda AV; Baggio JM; Ferreira LG; Gomes GG; Marin-Neto JA; Junqueira LF
    Europace; 2014 May; 16(5):674-80. PubMed ID: 24481778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
    Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
    Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of arrhythmia recurrence in patients presenting with ventricular fibrillation versus ventricular tachycardia in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial.
    Raitt MH; Klein RC; Wyse DG; Wilkoff BL; Beckman K; Epstein AE; Coromilas J; Friedman PL; Martins J; Ledingham RB; Greene HL;
    Am J Cardiol; 2003 Apr; 91(7):812-6. PubMed ID: 12667566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
    Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
    Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ
    Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial.
    Ruwald MH; Solomon SD; Foster E; Kutyifa V; Ruwald AC; Sherazi S; McNitt S; Jons C; Moss AJ; Zareba W
    Circulation; 2014 Dec; 130(25):2278-86. PubMed ID: 25301831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score.
    Younis A; Goldberger JJ; Kutyifa V; Zareba W; Polonsky B; Klein H; Aktas MK; Huang D; Daubert J; Estes M; Cannom D; McNitt S; Stein K; Goldenberg I
    Eur Heart J; 2021 May; 42(17):1676-1684. PubMed ID: 33417692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders.
    Anselme F; Moubarak G; Savouré A; Godin B; Borz B; Drouin-Garraud V; Gay A
    Heart Rhythm; 2013 Oct; 10(10):1492-8. PubMed ID: 23811080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Added Value of 3- Versus 2-Dimensional Echocardiography Left Ventricular Ejection Fraction to Predict Arrhythmic Risk in Patients With Left Ventricular Dysfunction.
    Rodríguez-Zanella H; Muraru D; Secco E; Boccalini F; Azzolina D; Aruta P; Surkova E; Genovese D; Cavalli G; Sammarco G; Ruozi N; Tenaglia RM; Calvillo-Argüelles O; Palermo C; Iliceto S; Badano LP
    JACC Cardiovasc Imaging; 2019 Oct; 12(10):1917-1926. PubMed ID: 30219408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients' Perspectives Regarding Generator Exchanges of Implantable Cardioverter Defibrillators.
    Montembeau SC; Merchant FM; Speight C; Kramer DB; Matlock DD; Horný M; Dickert NW; Rao BR
    Circ Cardiovasc Qual Outcomes; 2023 Aug; 16(8):509-518. PubMed ID: 37492959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamically Tolerated Ventricular Tachycardia With Mildly Impaired Ejection Fraction: Do These Patients Have VT/VF Recurrence and ICD Therapies?
    Gula LJ; Frydman A; Khan HR; Klein GJ; Leong-Sit P; Manlucu J; Roberts JD; Tang ASL; Yee R; Skanes AC
    Can J Cardiol; 2022 Aug; 38(8):1271-1276. PubMed ID: 35346798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival Probability and Survival Benefit Associated With Primary Prevention Implantable Cardioverter-Defibrillator Generator Changes.
    Bilchick KC; Wang Y; Curtis JP; Shadman R; Dardas TF; Anand I; Lund LH; Dahlström U; Sartipy U; Levy WC
    J Am Heart Assoc; 2022 Jul; 11(13):e023743. PubMed ID: 35766293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of appropriate shock after generator replacement in patients with an implantable cardioverter defibrillator.
    Arcinas LA; Chew DS; Seifer CM; Baranchuk A; Supel I; Exner DV; Boles U; McIntyre WF
    Pacing Clin Electrophysiol; 2021 May; 44(5):911-918. PubMed ID: 33826179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.